



Kilitch Drugs (India) Ltd.

Admin. Off. : 37, Ujagar Industrial Estate, W. T. Patil Marg, Deonar, Mumbai - 400 088.
• Tel. : +91-22-6121 4100 • Fax : +91-22-6703 1658
Regd. Off. : C-301/2, M.I.D.C., T.T.C. Industrial Area, Pawane Village, Navi Mumbai - 400 705. Maharashtra
& Factory • Tel. : +91-22-6514 4185 / 2768 0913 • Fax : +91-22-2768 0912
• E-mail : info@kilitch.com • Website : www.kilitch.com

May 14, 2012

To,
The Listing Department
National Stock Exchange of India Limited
Exchange Plaza, Plot no. C/1, G Block,
Bandra-Kurla Complex
Bandra (E), Mumbai - 400 051.

Respected Sir,

Scrip Code : KILITCH

Sub: OUTCOME OF THE BOARD MEETING HELD ON MONDAY, MAY 14, 2012.

With reference to the above captioned subject, we wish to intimate your esteemed exchange that as decided in the Meeting of the Board of Directors of the Company held on **Monday, May 14, 2012**, for which intimation was already given to you, it was decided:


- To adopt and approve the Unaudited (Provisional) Financial Results of the Company for the quarter ended 31st March 2012.

The above intimation is given to you for your record.

Thanking You,

Yours faithfully,
For **KILITCH DRUGS (INDIA) LIMITED**


MUKUND MEHTA
MANAGING DIRECTOR.



KILITCH DRUGS INDIA LIMITED- UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 31ST MARCH 2012


(Rupees in Lakhs)

PART II	Particular
A	PARTICULARS OF SHAREHOLD
1	Public shareholding
	Number of shares
	Percentage of shareholding
2	Promoters and Promoter Group St
a)	Pledge / Encumbered
	Number of shares
	Percentage of shares (as a %
	of promoter and promoter group)
	Percentage of shares (as a %
	of the company)
b)	Non-encumbered
	Number of shares
	Percentage of shares (as a %
	of promoter and promoter group)
	Percentage of shares (as a %
	of the company)

Particulars
B
INVESTOR COMPLAINTS
Pending at the beginning of the quarter
Received during the quarter
Disposed of during the quarter
Remaining unresolved at the end of

PART I	Particulars	STAND ALONE					CONSOLIDATED	
		3 MONTHS ENDED 31ST MARCH 2012	PRECEEDING 3MONTHS ENDED 31ST DEC 2011	YEAR TO DATE CURRENT PERIOD ENDED 31ST MARCH 2012	CORRESPONDING 3MONTHS ENDED 31ST MARCH 2011	YEAR TO DATE FIGURES PREVIOUS YEAR ENDED 31ST MARCH 2011	YEAR ENDED 31ST MARCH 2012	YEAR ENDED 31ST MARCH 2011
		UNAUDITED	UNAUDITED	UNAUDITED	UNAUDITED	AUDITED	UNAUDITED	AUDITED
1	Income from operations							
	(a) Net Sales/Income from operations(net of Excise)	1,839.42	2,741.91	10,682.07	5,090.93	14,599.53	10,880.12	14,630.17
	(b) Other operating income	0.00	0.00	0.00	0.00	0.00	0.00	0.00
	Total income from Operations (Net)	1,839.42	2,741.91	10,682.07	5,090.93	14,599.53	10,880.12	14,630.17
2	Expenses							
	(a) Cost of materials consumed	1,558.72	1,615.94	6,981.31	3,801.82	10,314.41	7,068.93	10,287.53
	(b) Purchased of Stock-in-trade							
	(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	-93.42	92.51	138.21	167.91	-217.03	138.21	-217.03
	(d) Employee benefits expenses	148.39	184.75	519.23	90.42	505.10	665.70	531.95
	(e) Depreciation and amortisation expenses	94.38	105.69	480.05	148.57	558.74	482.23	558.74
	(f) Other expenses (Any item exceeding 10% of the expenses relating to continuing operations to be shown separately)	719.17	311.75	2,107.89	635.35	1,784.20	2,235.00	1,820.74
	Total Expenses	2,427.22	2,310.64	10,226.69	4,843.87	12,945.42	10,590.12	12,881.93
	Profit / (Loss) from operations before other income, finance costs and exceptional items (1-2)	-787.80	431.27	455.38	247.06	1,654.11	290.00	1,848.24
3	Other Income	91.67	6.28	109.35	8.18	26.55	110.31	21.00
4	Profit / (Loss) from ordinary activities before finance cost and exceptional items (3+4)	-696.13	437.55	564.73	255.24	1,680.66	400.31	1,869.24
5	Finance Costs	114.06	112.89	302.75	76.13	372.53	303.52	357.62
6	Profit / (Loss) from ordinary activities after finance cost but before exceptional items (5-6)	-810.19	324.66	261.98	177.11	1,308.13	98.79	1,511.62
7	Exceptional Items	0.00	0.00	0.00	0.00	0.00	0.00	0.00
8	Profit / (Loss) from ordinary activities before tax (7+8)	-810.19	324.66	261.98	177.11	1,308.13	98.79	1,511.62
9	Tax Expenses		52.09	102.85	35.42	262.07	102.85	262.82
10	Net Profit / (Loss) from ordinary activities after tax (9-10)	-810.19	272.57	159.13	141.69	1,046.06	-6.06	1,048.80
11	Extra Ordinary Items (net of tax expenses Rs. Lakhs)	8,703.15		8,703.15			8,703.15	
12	Net Profit / (Loss) for the period (11+12)	7,892.96	272.57	8,862.28	141.69	1,046.06	8,697.09	1,048.80
13	Share of Profit / (Loss) of associates*							
14	Minority interest *							
15	Net Profit / (Loss) after taxes, minority interest and share of profit / (loss) of associates (13+14+15) *							
16	Share of profit / (loss) of associates (13+14+15) *	1323.18	1323.18	1323.18	1323.18	1323.18	1323.18	1323.18
17	Paid-Up equity share capital (Face Value of the Share shall be indicated)							
18	Reserve excluding Revaluation Reserve as per Balance sheet of previous accounting year							
19.i	Earnings per share (before extra ordinary items) (of Rs. 10 /-each) (not annualised):							
	(a) Basic	-6.12	2.06	1.20	1.07	7.91	-0.05	7.92
	(b) Diluted	-6.12	2.01	1.20	1.07	7.73	-0.05	7.74
19.ii	Earnings per share (after extra ordinary items) (of Rs. 10 /-each) (not annualised):							
	(a) Basic	59.79	2.06	66.98	1.07	7.91	65.73	7.92
	(b) Diluted	3.75	2.01	6.61	1.07	7.73	6.68	7.74

See accompanying note to the financial results



KILITCH DRUGS INDIA LIMITED- UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 31ST MARCH 2012
(Rupees in Lakhs)

	Stand Alone		Consolidated	
	As at 31st March 2012	As at 31st March 2011	As at 31st March 2012	As at 31st March 2011
A				
Statement of Assets and Liabilities				
EQUITY AND LIABILITIES				
1 Shareholders Funds	1,323.18	1,323.18	1,323.18	1,323.18
(a) Share Capital	15,944.38	7,121.54	15,813.88	7,107.40
(b) Reserve and Surplus	0.00	0.00	0.00	0.00
(c) Money received against share warrants	17,267.56	8,444.72	17,137.06	8,430.58
Sub-total - Shareholders' Funds	0.00	0.00	0.00	0.00
2 Share application money pending allotment	0.00	0.00	112.85	156.65
3 Minority Interest*	0.00	0.00	3.65	0.00
4 Non-current liabilities	0.00	0.00	0.00	0.00
(a) Long-term borrowings	0.00	0.00	51.57	158.58
(b) Deferred tax liabilities (net)	51.57	158.58	3,041.57	826.01
(c) Other long-term liabilities	3,040.82	825.26	3,096.79	984.57
(d) Long term provisions	3,092.39	983.82		
Sub Total-Non- current liabilities				
5 Current liabilities	0.00	5,305.71	3.33	5,305.71
(a) Short-term borrowings	263.34	1,261.91	268.60	1,264.77
(b) Trade Payables	972.19	0.00	999.28	16.48
(c) Other current liabilities	0.00	154.29	0.00	154.29
(d) Short- term provisions	1,235.63	6,721.91	1,271.21	6,741.25
Sub Total- current liabilities	0.00			
TOTAL- EQUITY AND LIABILITIES	21,595.48	16,150.45	21,617.91	16,313.05
B				
ASSETS				
1 Non-current assets	837.65	8,507.95	847.85	8,507.95
(a) Fixed Assets	0.00	0.00	0.00	0.00
(b) Goodwill on consolidation *	16.59	0.00	16.59	0.00
(c) Non-current investments	696.82	696.82	696.82	696.82
(d) Deferred tax assets (net)	10.53	8.68	10.53	8.68
(e) Long-term loans and advances	2,171.10	65.79	2,182.05	65.79
(f) Other non-current assets	3,732.69	9,279.24	3,753.84	9,279.24
Sub Total-Non- current assets				
2 Current assets	14,003.18	218.08	13,812.81	21.84
(a) Current investments	193.81	1,675.62	230.85	1,702.50
(b) Inventories	2,462.66	3,844.85	2,509.28	3,869.61
(c) Trade receivables	1,160.72	932.94	1,163.49	948.97
(d) Cash and cash equivalents	42.42	185.02	147.66	426.54
(e) Short-term loans and advances	0.00	14.70	0.00	64.35
(f) Other current assets	17,862.79	6,871.21	17,864.07	7,033.81
Sub Total- current assets	21,595.48	16,150.45	21,617.91	16,313.05
TOTAL AS				

See accompanying note to the financial results

*Applicable in the case of consolidated statement of assets and liabilities.

- Notes:
- The above results after being reviewed by the audit committee have been approved and taken on record by the Board of Directors at its meeting held on 14th May 2012 and are subject to limited review by the auditors.
 - The previous years/period figures have been regrouped and reclassified wherever required to conform with current year/period figures.
 - The Company has only one primary reportable segment-Pharmaceuticals.
 - During the year/quarter the Company has sold off its Ppanta Sahib plant as a going concern and the profit on such sale is shown under extra ordinary income.

By and on Behalf of the Board
For Kilitch Drugs (India) Ltd.

Mukund P Mehta
Managing Director

Place : Mumbai
Date: 14th May 2012

